NCI Broadens the Pool of Oncologists Enrolling Patients in Phase III Trials

Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

BETHESDA, Md-To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

BETHESDA, Md—To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

Under EPP, qualified oncologists can enter patients in 16 large clinical trials for breast, lung, prostate, and colorectal cancer. Other phase III trials will be opened up to EPP participating physicians later this year.

The program offers a simplified, Internet-based process for enrolling patients and a direct reimbursement of $1,500 per patient to physicians to cover their research-related time and costs.

NCI expects EPP to become a national program that will significantly reduce the time it takes to accrue the hundreds or thousands of patients necessary for phase III studies. Additional information is available on the EPP website located at http://light.emmes.com/epp

Related Videos
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Experts on multiple myeloma
Expert on prostate cancer
Experts on multiple myeloma
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
Andre H. Goy, MD, an expert on B-cell malignancies
Related Content